NCT02655224View on ClinicalTrials.gov

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 26, 2016

Primary Completion Date

May 16, 2017

Study Completion Date

May 19, 2017

Conditions
Uterine Fibroids
Interventions
DRUG

Relugolix

Relugolix Tablets

DRUG

Relugolix placebo

Relugolix placebo-matching tablets

Trial Locations (11)

Unknown

Matsudo

Ebetsu

Sapporo

Nishinomiya

Ibaraki

Sakai

Bunkyo-ku

Minato-ku

Setagaya-ku

Kagoshima

Osaka

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02655224 - A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | Biotech Hunter | Biotech Hunter